Folate receptor test for high-grade ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at a protein called folate receptor alpha on ovarian cancer cells. It aims to understand how common this protein is, which could help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female.
- You are 18 years old or older.
- You have been diagnosed with high-grade serous epithelial ovarian cancer by a pathologist.
- Your tissue sample is of good quality and sufficient quantity for analysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a protein called RPL8 in a specific type of ovarian cancer called high-grade serous ovarian carcinoma. It may help researchers understand the disease better and find new ways to treat it.
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
This study looks at whether a standard cervical smear test can help find ovarian cancer earlier. The test searches for genetic changes linked to high-grade serous ovarian cancer in cells collected from the cervix, possibly enabling earlier diagnosis.
This study checks whether a blood test (ctDNA) can show how well ovarian, fallopian tube, or primary peritoneal cancer treatment is working. If the test reliably reflects response, it could help doctors adjust treatment earlier and more precisely.
This study examines tissue samples from women with a specific type of ovarian cancer (high-grade serous) to measure how much of a protein called folate receptor alpha is present. Understanding this protein level may help doctors identify which patients could benefit from targeted treatments in the future.
This study looks at a marker called folate receptor alpha in tissue samples from people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. The goal is to see how common this marker is, which may help guide future treatment options.
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.